Metasens VG 2mg Tablet is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, which aids in better glucose utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, resulting in reduced postprandial hyperglycemia. This combination therapy provides a multifaceted approach to glycemic control by targeting different pathophysiological mechanisms of type 2 diabetes. Metasens VG 2mg is typically prescribed when monotherapy with either agent is insufficient to achieve adequate glycemic control. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypoglycemia, particularly due to Glimepiride. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in cases of diabetic ketoacidosis or severe metabolic acidosis. Patient adherence to diet, exercise, and regular monitoring is critical for optimal outcomes with Metasens VG 2mg Tablet.